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Introduction
!
Pancreatic cystic lesions (PCLs) are divided into
two main classes, cystic mucinous neoplasms
(CMNs) and non-mucinous cysts. CMNs consist
of intraductal papillary mucinous neoplasms
(IPMNs) and mucinous cystic neoplasm (MCNs).
Mucinous and non-mucinous classification is ex-
tremely important since these cysts are premalig-
nant neoplasms with potential for progression to
pancreatic cancer.
Cross-sectional imaging methods and particularly
endoscopic ultrasonography (EUS) have a signifi-
cant role in diagnosis and differentiation of PCLs
[1,2]. However, there are some limitations to ima-
ging alone and imaging may not be helpful in dif-
ferentiating between various types of cysts. EUS
fine-needle aspiration (EUS-FNA) of cystic lesions
allows for biochemical and cytological analysis of
cyst fluid that might be further helpful for differ-
entiation [2,3]. Among all cyst fluid diagnostic
parameters, pancreatic cyst fluid (PCF) carci-
noembryonic antigen (CEA) concentration alone
has been suggested as the most accurate test for
the diagnosis of CMNs at a cut-off level of 192ng/
mL. However, the diagnostic sensitivity of PCF
CEA at a cut-off level of 192ng/mL has been re-
ported to be less than 60% in recent clinical series
[4–6].
The presence of KRAS mutation in PCF in recent
studies has been suggested as a highly specific
test for the classification of a cyst as mucinous
[7–9]. However, the number of patients included
in some studies was small, with a limited number
of studies using histology as the diagnostic ‘refer-
ence standard [8–11]. Therefore, based on cur-
rent reports, it is not certainwhether routine test-
ing for KRAS mutations in PCF is warranted. Our
study primarily aimed to assess the value of
KRAS mutational analysis along with CEA in PCF
for accurate diagnosis of mucinous cysts. The
study also sought to assess the value of KRASmu-
tation analysis in the differentiation of malignant
CMNs.
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Background and aims: Pancreatic cyst fluid (PCF)
CEA has been shown to be the most accurate pre-
operative test for detection of cystic mucinous
neoplasms (CMNs). This study aimed to assess
the added value of PCF KRAS mutational analysis
to CEA for diagnosis of CMNs.
Patients and methods: This is a retrospective
study of prospectively collected endoscopic ultra-
sonography (EUS) fine-needle aspiration (FNA)
data. KRASmutationwas determined by direct se-
quencing or equivalent methods. Cysts were clas-
sified histologically (surgical cohort) or by clinical
(EUS or FNA) findings (clinical cohort). Perform-
ance characteristics of KRAS, CEA and their com-
bination for detection of a cystic mucinous neo-
plasm (CMN) and malignancy were calculated.
Results: The study cohort consisted of 943 pa-
tients: 147 in the surgical cohort and 796 in the
clinical cohort. Overall, KRAS and CEA each had
high specificity (100% and 93.2%), but low sensi-
tivity (48.3% and 56.3%) for the diagnosis of a
CMN. The positivity of KRAS or CEA increased the
diagnostic accuracy (80.8%) and AUC (0.84) sig-
nificantly compared to KRAS (65.3% and 0.74) or
CEA (65.8% and 0.74) alone, but only in the clini-
cal cohort (P<0.0001 for both). KRAS mutation
was significantly more frequent in malignant
CMNs compared to histologically confirmed non-
malignant CMNs (73% vs. 37%, P=0.001). The
negative predictive value of KRAS mutation was
77.6% in differentiating non-malignant cysts.
Conclusions: The detection of a KRASmutation in
PCF is a highly specific test for mucinous cysts. It
outperforms CEA for sensitivity in mucinous cyst
diagnosis, but the data does not support its rou-
tine use.
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Patients and methods
!
The study is a retrospective analysis of prospectively collected
EUS-FNA data from two academic medical centers, Massachu-
setts General Hospital, (MGH) and Indiana University (IU). Pa-
tients gave their consent for FNA of the cyst and for fluid analysis,
and a cyst registry was approved by the Institutional Review
Boards (IRB) at both institutions. Consecutive patients who un-
derwent an EUS-FNA for PCLs between 2006–2014 and who
had sufficient fluid for KRAS mutation analysis were enrolled in
the study. Exclusion criteria included patients with a bleeding
tendency (INR>1.5, partial thromboplastin time >50 sec or plate-
lets <50,000mm3), a solid mass, a history of pancreatic cancer,
acute pancreatitis, a high clinical suspicion of a pseudocyst or
pancreatic abscess, pancreatic ductal adenocarcinomawith cystic
degeneration, cysts of extra-pancreatic origin and fluid provided
by FNA of the main pancreatic duct.
The study data were recorded in a prospectively maintained da-
tabase and the patients were divided into two separate groups
for all analysis according to their management. Patients who un-
derwent a surgical resectionwere included in the surgical cohort,
and patients who were managed non-surgically included in the
clinical cohort.
EUS-FNA
Patients who had a PCL≥10mm on cross-sectional imaging, and
who were referred for EUS-FNA made up the study population.
The location, size, number and morphology (mural nodule, wall
thickness, septations, adjacent mass, ductal communication) of
cysts was recorded. EUS-FNA was attempted if the cyst diameter
was≥10mm and if the results could potentially impact patient
management. The PCF was triaged for cytological examination
and biochemical (CEA and amylase) analysis first and then for
molecular testing. KRAS mutation testing was performed selec-
tively when the fluid volume was more than 0.5mL.
To allow comparison of accuracy with KRAS analysis, cyst fluid
CEA level was not used as a reference to differentiate mucinous
cysts in the clinical cohort. A cut-off CEA value of 192ng/mL was
considered positive for only diagnostic calculations.
Pathology and cytology
Cysts were classified by histological examination as either muci-
nous (main-duct (MD), branch-duct (BD) or combined (COM)
[IPMNorMCN]) or non-mucinous cysts (serous, pseudocyst, neu-
roendocrine and others). IPMNs were further subclassified ac-
cording to the degree of dysplasia using 2010 WHO criteria [12];
(i) IPMN with low- or intermediate-grade dysplasia, (ii) IPMN
with high-grade dysplasia (HGD), and (iii) IPMNwith an associat-
ed invasive carcinoma. Malignant cysts were defined as cysts
with either HGD or invasive carcinoma.
Cytological analyses of PCF were reported as non-diagnostic (be-
cause of insufficient cells or contamination) or diagnostic (ade-
quate for evaluation of cellular elements). Diagnostic samples
were classified either as mucinous (thick, colloid-like extracellu-
lar mucin without cells, mucinous epithelium with cytoplasmic
mucin, low-grade mucinous epithelium in a transduodenal FNA,
high-grade atypia or adenocarcinoma) or non-mucinous [13].
Nonspecific gastric-foveolar type epitheliumwithout thick extra-
cellular mucin in the transgastric FNAs was defined as nondiag-
nostic.
Classification of cysts
The mucinous/non-mucinous cyst classification of cysts in the
surgical cohort was based on surgical histology results. The cysts
in the clinical cohort were classified as mucinous if they had one
of the cytological criteria (thick, colloid-like extra-cellular mucin
without cells, mucinous epithelium with cytoplasmic mucin,
low-grade mucinous epithelium in a transduodenal FNA, high-
grade atypia or adenocarcinoma) or one of the EUS criteria [14]
(mural nodule, wall thickness, septations, adjacent mass, ductal
communication). These criteria are summarized in ●" Table1.
The cysts without any cytological or EUS criteria for a mucinous
cyst were classified as non-mucinous.
KRAS analysis
KRAS 2-point mutation analysis on codons 12 and 13 was deter-
mined by fluorescent-based direct sequencing (PathFinder TG®;
Redpath, Pittsburgh, PA, USA) for all cases from IU, and for cases
from MGH until the year 2010 by using the method previously
described [7]. Starting in 2010, KRAS analysis on codons 12 and
13 was performed by using a primer extension-based method
(SNaPshot® Life Technologies) in the Molecular Pathology De-
partment of MGH. PCF with no amplification or no mutation
were accepted as KRAS mutation negative which represents
wild-type KRAS.
Surgery
All patients with a clinical diagnosis of MCN, MD-IPMN, or COM-
IPMN were referred for surgical resection if they were good sur-
gical candidates. Patients with BD-IPMNs were evaluated and re-
ferred to surgery according to International Consensus Guide-
lines from 2006 [15] and then 2012 [16].
Data analysis
The sensitivity, specificity, positive predictive value (PPV), nega-
tive predictive value (NPV) and diagnostic accuracy of KRAS, CEA
and their combination for the diagnosis of a mucinous cyst were
calculated. The true positivity and false positivity was accepted
with the positivity of one of the tests. Receiver-operator curves
were generated and the area under the curve (AUC) calculated
for diagnostic value of the tests. AUC values of tests and their
combinations were compared statistically. Comparisons between
categorical variables were tested with Chi Square test. Indepen-
dent Student t-test was used to compare mean values between
two independent groups. The agreement between CEA and
KRAS to differentiate mucinous cysts was measured by concor-
dance correlation coefficient. An rc value of 1 represents perfect
agreement and 0 represents the agreement expected from
chance. A 2-tailed P value<0.05 was considered statistically sig-
Table 1 Diagnostic criteria for mucinous cysts in non-surgical cohort.
Endosono-
graphic criteria
– Mural nodule
– Wall thickness
– Septations
– Adjacent mass
– Ductal communication
Cytological
criteria
– Thick, colloid-like extracellular mucin without
cells
– Mucinous epithelium with cytoplasmic mucin
– Low-grade mucinous, epithelium in a
transduodenal FNA
– High-grade atypia or adenocarcinoma
Abbreviation: FNA, fine-need aspiration
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nificant. SPSS 15.0 package program (2006 SPSS Inc., Chicago, IL)
was used for statistical analysis.
Results
!
A total of 2750 patients underwent an EUS-FNA of a pancreatic
cyst during the study period, of whom data on 943 with a KRAS
mutation analysis result were available for analysis (the molecu-
lar analysis results of 282 cases from IU have been previously re-
ported [17]). Patients were excluded from KRAS testing due to in-
sufficient PCF volume, the gastroenterologist’s decision not to
test for KRAS mutation which was based on clinical findings, or
due to technical failures of the test.
One hundred and forty-seven patients with a KRAS mutation a-
nalysis underwent surgical resection and made up the surgical
cohort. The remaining 796 cases were classified by EUS findings
or cytological results and they made up the clinical cohort. A
flowchart of the study population is shown in●" Fig.1. Mucinous
cysts constituted 73.4% (108/147) of patients in the surgical co-
hort and 67.7% (539/796) of patients in the clinical cohort. Cyst
fluid CEA level>192mg/dL plays a key diagnostic role in muci-
nous cyst definition but we did not use it for the basic classifica-
tion to avoid a flaw in the methods. However, the addition of CEA
criteria to cytology plus EUS for a mucinous definition added 11
more cases to the mucinous group in the clinical cohort. These
changes did not affect the overall performance of KRAS or KRAS
+CEA in this cohort.
Baseline demographics, clinical and cyst characteristics of the
study cohorts, based on mucinous classification, are provided in
●" Table2.
Surgical pathology and cytology
Mucinous cysts were malignant in 27 (invasive carcinoma in 19,
and high-grade dysplasia in 8) of the patients based on the surgi-
cal pathology. Malignancy was identified in three cases of MCN.
Cytological evaluation was non-diagnostic in 201 (25.2%) of the
clinical cohort because of inadequate or acellular material. A mu-
cinous cyst was defined in 26% (207/796) of the clinical cohort by
cytology (adenocarcinoma in 15, high-grade atypia in 14, and by
other cytological criteria in 178 cases) and 41.7% (332/796) by
EUS criteria. Two hundred and fifty-seven patients in the clinical
cohort (32.3%) had none of the cytological or EUS criteria for a
mucinous cyst, and their disease was classified as non-mucinous.
KRAS and CEA diagnostic results
The sensitivity, specificity, PPV, NPV, diagnostic accuracy and
AUC value of KRAS positivity, CEA elevation and their combina-
tion for the diagnosis of a mucinous cyst as a whole and for each
cohort are provided in●" Table3. The PCF CEA level at a 192ng/
mL cut-off value was highly specific at 93.2% but the sensitivity
was found to be 56.3% in the whole group.The sensitivity of PCF
CEA for amucinous cyst diagnosis was lower in the clinical cohort
than in the surgical cohort (54.6% vs. 63.2%, P=0.03). The sensi-
tivity of KRAS for a mucinous cyst diagnosis was 46.3% (50/108)
and 48.8% (263/539) for the surgical and clinical cohorts, respec-
tively, and the specificity was 100% for both. Adding the KRAS re-
sult to the CEA result increased the sensitivity to 13.8% in the sur-
gical cohort and 21% in the clinical cohort. The diagnostic accura-
cy of the combined tests was more than 80% in all cohorts. The
increased diagnostic accuracy and AUC with the KRAS-CEA com-
bination was statistically significant compared to KRAS and CEA
alone in the clinical cohort. The study parameters and assay re-
sults based on histological subtypes are shown in●" Table4. The
KRAS positivity rate was higher in patients with IPMN than in
those with MCN but the results were not statistically significant
(49.4% vs. 33.3%, P=0.27). KRAS mutation was positive in 12 pa-
tients in the surgical cohort and in 74 patients in the clinical co-
hort when CEA level is under 192mg/dL. The correlation coeffi-
cient rc was 0.23 for the surgical and 0.28 for the clinical cohorts,
which demonstrated a weak correlation between KRAS and CEA
results. The KRAS positivity and CEA levels did not show any cor-
relation with the size, number and location of the cysts.
KRAS and CEA in malignant cysts
Based on histology and cytology, there were 56 patients with a
malignant cyst (34 patients with adenocarcinoma and 22 pa-
tients with high-grade dysplasia/atypia) in the study population.
The surgical cohort had 19 patients with adenocarcinoma and 8
patients with high-grade dysplasia. The clinical cohort had 15 pa-
tients with adenocarcinoma and 14 patients with high-grade
atypia. KRASmutationwas positive in 73.2% (41/56) of malignant
cysts. However, KRAS mutations were found in 37.3% (31/83) of
surgically confirmed benign mucinous cysts. KRAS mutations
were significantly more frequent in malignant mucinous cysts
compared to benign mucinous cysts (73.2% vs. 37.3%, P=0.001).
Having a KRASmutation in a mucinous cyst increased the relative
risk of a malignant cyst to 1.96 (1.42<RR<2.70) and odds ratio to
5.58 (2.06<OR<10.32). In malignant cysts, KRAS mutation rate
was higher in patients with adenocarcinoma (28/34, 82.3%)
Total population  with  FNA of pancreas  cyst (n = 2750)
Study population with a KRAS result (n = 943)
Mucinous cyst 
(n = 108)
Non-mucinous cyst 
(n = 39)
IPMN (n = 87)
MCN (n = 21)
Serous cyst (n = 9)
Pseudocyst (n = 8) 
Neuroendocrine (n = 12)
Others (n = 10)
Mucinous cyst 
(n = 539)
Surgical resection (n = 147) Non-surgical management (n = 796)
Non-mucinous cyst
(n = 257)
Fig.1 Flowchart of the study population.
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than patients with high-grade dysplasia/atypia (13/22, 59%). The
study parameters between malignant cysts and surgically con-
firmed benign cysts are shown in●" Table5. Elevated PCF CEA
level was found more frequently in malignant mucinous cysts
compared to benign cysts (78.5% vs. 57.8%, P=0.02). The median
CEA values of malignant cysts were also significantly higher than
non-malignant cysts (921mg/dL vs. 491mg/dL, P=0.04).
The combination of KRAS and CEA revealed 91% sensitivity but
30.1% specificity for a malignant cyst diagnosis. The NPV of
KRAS mutation alone and together with CEA elevation was 77.6
% and 83.3%, respectively, in differentiating non-malignant from
malignant CMNs.
Discussion
!
The accurate diagnosis of PCLs is a key challenging issue for opti-
mal clinical management. The high specificity of KRAS mutation
for mucinous cysts has been confirmed in subsequent clinical
studies but low sensitivity limited its widespread usage in rou-
tine PCF analysis [10, 18].
To our knowledge, the current study includes the largest cohort
of KRAS mutation testing for CMN diagnosis. The results of our
study confirmed high specificity of KRAS mutation for MCNs di-
agnosis in both surgical and clinical cohorts. However, the sensi-
tivity of KRAS mutation alone was limited. The PCF CEA (cutoff
192ng/mL) was also highly specific for mucinous cysts but the
Table 3 Diagnostic value of CEA and KRAS to differentiate mucinous vs. non-mucinous cysts.
All patients n=943 Surgical cohort n=147 Clinical cohort n=796
Test KRAS+ CEA↑ KRAS+or
CEA↑
KRAS+ CEA↑ KRAS+or
CEA↑
KRAS+ CEA↑ KRAS+or
CEA↑
Sensitivity % 48.3 56.3 75.8 46.3 63.2 77 48.8 54.6 75.6
Specificity % 100 93.2 93.2 100 90.9 91.1 100 93.8 93.8
PPV % 100 95.4 96.6 100 94.8 95.7 100 95.6 96.8
NPV % 47 45.9 60.6 40.2 48.3 60.7 48.2 45.2 60.5
Accuracy % 64.5 66.8 80.9* 60.5 70.8 81.6^ 65.3 65.8 80.81
AUC 0.742 0.748 0.846* 0.730 0.781 0.838~ 0.744 0.742 0.8471
Abbreviation: PPV, positive predictive value; NPV, negative predictive value; AUC, area under curve
1 P<0.0001 vs. KRAS+and CEA↑ alone, ^P<0.01 vs KRAS+ ,>0.05 vs CEA↑ alone, ~P>0.05 vs. KRAS+and CEA↑ alone
Table 2 Demographic, clinical and cyst characteristics of the study cohorts based on the mucinous classification.
Surgical cohort Clinical cohort
Total Mucinous Non-mucinous p Mucinous Non-muci-
nous
p
Number (n) 943 108 39 539 257
Mean age (range), years 66.4
(17–95)
61.9
(20–89)
56.4
(27–77)
P=0.053 70.3
(17–95)
61.2
(23–88)
P=0.0001
Gender, male/female 384/559 36/72 17/22 P=0.68 222/317 109/148 P=0.8
Symptomatic1, n (%) 524 (56.2) 70 (64.8) 21 (53.8) P=0.42 296 (54.9) 143 (55.6) P=0.9
Amylase >250mg/dL, (%) 68.2 55.7 53.1 P=0.97 74.5 63.7 P=0.02
Cyst size (mean diameter ± SD), mm 25.3 ± 16 27±15 23±14 P=0.45 24±17 22±15 P=0.13
Cyst location (%)
Head/neck/Unc.
Body
Tail
55
24
21
40
24
36
32
21
47
P=0.69
58
25
17
55
23
22
P=0.48
Cyst number (%)
Single
Multiple
69
31
70
30
75
25
P=0.95 66
34
74
26
P=0.09
1 One of the symptoms referable to the pancreas; abdominal pain, weight loss, obstructive jaundice, pancreatitis.
Table 4 Study parameters based on histological cyst type (n =147).
Parameters IPMN MCN Serous Pseudocyst NET Others
Number (n) 87 21 9 8 12 10
Mean age (range), years 66.3 (29–89) 45.3 (20–70) 51.8 (27–75) 57.8 (30–66) 62.2 (40–77) 53.1 (28–70)
Gender, male/female 35/52 1/20 3/6 4/4 8/4 2/8
KRAS (+), % 49.4 33.3 0 0 0 0
CEA>192mg/dL, (%) 61.9 68.4 0 12.5 16.6 10
KRAS (+) or CEA↑ (%) 77 73.6 0 12.5 16.6 10
Amylase >250mg/dL, (%) 53.7 64.7 37.5 75 25 77
Abbreviations: IPMN, intraductal papillary neoplasms; MCN, mucinous cystic neoplasm; NET, neuroendocrine tumor
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sensitivity was found to be lower than previously reported by the
Cooperative Study [14]. The sensitivity of CEA for mucinous cysts
diagnosis in the surgical cohort was higher than in the clinical co-
hort in our study. This might be a result of a selection bias of pa-
tients for surgery including malignant mucinous cysts andMCNs.
A meta-analysis of 12 published studies showed that the pooled
sensitivity and specificity of CEA for the differentiation between
mucinous and non-mucinous cystic lesions was 63% and 88%,
respectively [19]. Most of these studies included surgically re-
sected lesions because there is no optimal diagnostic standard
for diagnosis of mucinous cyst in a clinical setting. As a result,
these published series usually consisted of patients with malig-
nant IPMNs, MCNs and BD-IPMNs with high-risk stigmata or
worrisome features. In our study, we have found that CEA eleva-
tion was significantly more common in malignant mucinous
cysts compared to non-malignant mucinous cysts.
The additive value of KRASmutation testing to PCF CEAmay have
potential to increase the sensitivity for diagnosis of mucinous
cysts. The combination of elevated CEA and KRAS mutation de-
tected an additional 11 mucinous cysts in 76 cases in the PANDA
study [7]. In another study, the sensitivity of KRAS mutation and
elevated CEA for mucinous differentiation were 54% and 62%,
respectively, and the combination of both improved the sensitiv-
ity to 83% and maintained a high specificity of 85% [10]. In our
study, the addition of KRAS analysis to CEA increased the sensi-
tivity and diagnostic accuracy of CEA significantly without de-
creasing specificity. The ROC analysis also showed significantly
larger AUC values with the combination of tests. However, we
could not demonstrate a statistical difference in diagnostic
parameters with use of combination tests in the surgical cohort.
In fact, sensitivity, diagnostic accuracy and AUC values of com-
bined tests were very similar between the surgical and the clini-
cal cohorts. There could be two reasons for the lack of a statistical
significance in the surgical cohort. First, the sensitivity of CEA
alone for diagnosis of a mucinous cyst was higher in the surgical
cohort than in the clinical cohort, whichmay have limited the ad-
ded benefit of KRAS analysis to the CEA testing. Second, the sam-
ple size was smaller in the surgical cohort than in the clinical co-
hort, which decreased the power of the analysis to detect a statis-
tical significance.
To detect the malignant potential of pancreatic cysts accurately is
the ultimate goal of any diagnostic test. KRAS mutation was
shown as one of the earliest genetic alterations in the majority
of pancreatic ductal adenocarcinomas but its role and presence
in the development of malignant cyst lacks clarity. The role of
cyst fluid KRAS mutation for assessment of malignancy was first
studied in 11 patients with malignant cysts, and was reported as
positive in 10 of these cases [20]. The number of DNA mutations
was found to be higher inmalignant cysts in the PANDA study but
the presence of KRAS mutation alone did not significantly differ
between premalignant and malignant cysts [7]. The high-ampli-
tude KRAS mutation followed by allelic loss was highly specific
for the presence of malignancy (96%) but the sensitivity re-
mained low (37%). The presence of PCF KRASmutation was asso-
ciated with progression and development of malignancy in long-
term follow-up of 63 patients in another study by the same group
[21]. Our data showed a high frequency of KRASmutation in ma-
lignant cysts. Unlike the PANDA study, both low- and high-clon-
ality mutations of KRASwere accepted as positive in our analysis.
This may explain the higher sensitivity and lower specificity of
KRASmutation in our study for malignant cyst detection. Another
interesting finding in our study was that cysts with high-grade
dysplasia/atypia had a higher KRAS mutation rate than did non-
malignant cysts but a lower rate than adenocarcinomas. The
number of cases with high-grade dysplasia/atypia was too small
to make a conclusion, but a possible role of KRAS mutation in
adenocarcinoma sequencing seems likely. KRAS mutation may
be one of the important tests predicting mucinous cyst behavior,
but our data show that the diagnostic value of KRAS positivity
alone for malignant cysts remains limited since it lacks specificity
for malignant non-malignant differentiation. Nevertheless, high
NPV might be helpful to exclude a malignant cyst in clinical prac-
tice. The combination of KRAS positivity with CEA does not add
diagnostic accuracy for malignant cysts but sensitivity and NPV
increased to 90.9% and 80.9%, respectively. The integration of
molecular pathology with cytology, imaging and fluid chemistry
determined the diagnosis of malignancy with a 90.6% sensitivity,
83.3% specificity and 89.6% accuracy [22].
GNASmutation has been detected in PCF samples of patients with
IPMN but not in fluid samples of other PCLs in recent studies [23].
It has high specificity but a limited sensitivity for a diagnosis of
IPMN. The combination of KRAS and GNASmutation analyses im-
proved the sensitivity of molecular testing in preliminary studies
[23,24]; however, more data are still needed to demonstrate the
benefit of a combination.
There are certain limitations to this study. Because surgical pa-
thology was the reference standard for a mucinous cyst diagno-
sis, the results of the surgical cohort, no doubt, will be more valu-
able. Our study included a significant number of patients but the
majority of themwere in the clinical cohort in whom a final mu-
cinous/non-mucinous classificationwas solely based on EUS and/
or cytological criteria. To avoid introducing bias to the methods,
we did not use CEA level and KRASmutation for cyst classification
in the clinical cohort. The specificity of cytology for mucinous
cyst diagnosis using the defined study criteria is very high; how-
ever, it underestimates the number of mucinous cysts due to low
sensitivity [3]. The EUS criteria used to define mucinous cysts are
useful in clinical practice but their specificity and sensitivity are
also limited. Therefore some of the mucinous cysts may have
been included in the non-mucinous group.
Table 5 Study parameters in
patients with malignant vs. non-
malignant mucinous cysts.
Parameters Malignant mucinous cysts
(surgical pathology or cytology)
Non-malignant mucinous cysts
(surgical pathology)
P
Number (n) 56 83
Mean age (range), years 73.1 (44–91) 62.3 (20–89) P=0.002
Gender, male/female 20/36 24/59 P=0.6
KRAS (+), % 73.2 37.3 P=0.001
CEA (median, mg/dL) 921 (4.5–168.140) 491 (0.3–48.378) P=0.04
CEA >192mg/dl, (%) 78.5 57.8 P=0.02
KRAS (+) or CEA↑ (%) 91 69.8 P=0.01
Amylase > 250mg/dL, (%) 29.8 59.4 P=0.01
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On the other hand, the studywas conducted in two tertiary refer-
ral high-volume centers where all EUSwere performed by highly
skilled endosonographers in the field. In clinical practice, only a
small proportion of pancreas cysts patients undergo surgery,
thus limiting the sample size for an adequate power analysis. For
this reason, well-designed studies need to include patients with a
non-surgical diagnosis. Besides, the results of selected patients
for surgery may be different than the unselected clinical cohort,
and surgical results may not be applicable to all patients with
pancreatic cysts. Therefore, we believe the sample size of our clin-
ical cohort is sufficient to make a conclusion about the utilization
of KRAS analysis.
Another limitation of this study was that the KRAS testing was
not studied in all cysts but on a selected basis. This may limit the
applicability of our results for all pancreatic cysts detected in
EUS.The retrospective analysis of the outcomes data from the
study databases was another drawback of the study. In spite of
the prospective collection of data, some missing or insufficient
data could undermine the study objectives. The analysis of KRAS
mutation by two different methods is another potential weak-
ness of the study. However, the comparison of the SNaPshot gen-
otyping system with direct DNA sequencing showed 100% con-
sistency in the validation study [25]. Performance characteristics
of different KRAS mutation analysis techniques including both
methods were found to be highly concordant [26]. We do not
think the use of KRAS analysis based on two different methods
has an impact on our study results because both methods are re-
liable and were validated in different studies.
In summary, the detection of a KRAS mutation in PCF is a highly
specific test for mucinous cysts. The addition of KRAS testing to
CEA outperforms its sensitivity but does not improve the diag-
nostic accuracy in the surgical cohort. KRAS mutations are more
frequently detected in malignant mucinous cysts than in non-
malignant cysts but the diagnostic accuracy is limited because of
low specificity. In conclusion, our data do not support routine use
of KRAS testing in traditional PCF analysis, but it might be poten-
tially useful in selected cases.
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